1. Home
  2. Research Themes
  3. Clinical integration
  1. Home
  2. Research Themes
  3. Clinical integration

Clinical integration involves creating a seamless connection between clinical and discovery science to maximise the value of patient data and samples.

Our goal is to foster close collaboration between researchers and clinicians, designing experiments and clinical trials that enhance both scientific understanding and cancer patient outcomes.  

Prof James Brenton leads a partnership between Addenbrooke’s Hospital, GE Healthcare, and the University of Cambridge to develop the GE Edison Health Services platform. This platform integrates data from electronic health records, radiology, and genomic results, making patient information easily accessible in one place. AI algorithms on this platform help to refine and explain patient data, aiding clinicians in their decisions. 

 The IMAXT Cancer Grand Challenge, led by Prof Greg Hannon, has created the first 3D tumour virtual reality tool by bringing together experts from diverse fields such as medicine, molecular biology, astronomy and programming. This innovative tool aims to provide a comprehensive view of a patient’s tumour structure and behaviour.  

 For the Wellcome LEAP Delta Tissue project, the Hannon Group is studying samples from patients with Triple Negative Breast Cancer before and after treatment. They are collecting data from these samples and combining it with information from other methods to create a model that predicts how patients will respond to treatments based on their initial samples. 

We aim to develop an integrated discovery ecosystem that ensures patient data and samples are used to their fullest potential. We are focused on ensuring that any diagnostic or predictive tools we develop are ready for use in clinical settings. This means designing these tools to meet the standards required for certification as medical devices from the start of the project. In our biomarker studies, we plan extensive validation and ensure the procedures used are clinically certified, making them reliable and ready for patient care.  

 By integrating clinical and discovery science we aim to improve cancer research and treatment, ultimately improving patient outcomes.